Velleca Mark A. 4

What Happened

• Mark A. Velleca, President & CEO and a director of Black Diamond Therapeutics (BDTX), was granted a derivative equity award covering 600,000 shares on January 21, 2026. The filing reports $0.00 consideration for the award (i.e., no cash paid at grant). This is an equity grant (option/award), not an open-market purchase or sale.

Key Details

• Transaction date: January 21, 2026. Form 4 filed January 23, 2026 (appears within the standard two-business-day filing window).
• Reported acquisition: 600,000 shares; reported price: $0.00; transaction type: A (award/grant — derivative).
• Vesting (footnote): 25% of the shares vest and become exercisable on January 21, 2027; the remainder vests in 36 equal monthly installments thereafter, subject to continued service.
• Shares owned after the transaction: not specified in the details provided in this summary.
• No indication this was a cashless exercise, sale, gift, or covered by a 10b5-1 plan in the provided filing.

Context

• This is an executive equity grant (likely options or similar derivative) with a multi-year vesting schedule intended to incentivize continued service. It is not an immediate stock purchase or sale and does not by itself indicate the executive bought or sold shares on the open market.